Eli Lilly and Company Total Liabilities
Eli Lilly and Company total liabilities. Based on the latest financial reports, Eli Lilly and Company (LLY) has total liabilities worth $108.40 Billion USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Eli Lilly and Company liquidity resilience to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Eli Lilly and Company (1985–2025)
Total liabilities of Eli Lilly and Company from 1985 to 2025. This chart illustrates how Eli Lilly and Company's total liabilities have evolved over time, based on quarterly financial data. Explore Eli Lilly and Company (LLY) long-term investment share to see how much of total assets are deployed in long-term investments.
Eli Lilly and Company Competitors by Total Liabilities
The table below lists competitors of Eli Lilly and Company ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Alphabet Inc Class C
NASDAQ:GOOG
|
USA | $281.50 Billion |
|
Tesla Inc
NASDAQ:TSLA
|
USA | $61.06 Billion |
|
Meta Platforms Inc.
SA:M1TA34
|
Brazil | R$188.74 Billion |
|
Meta Platforms Inc.
NASDAQ:META
|
USA | $188.74 Billion |
|
Space Exploration Technologies Corp. Class A Common Stock
NASDAQ:SPCX
|
USA | $65.55 Billion |
|
SK Hynix Inc. American Depositary Shares
NASDAQ:SKHY
|
USA | $86.17 Trillion |
|
Walmart Inc
SA:WALM34
|
Brazil | R$192.56 Billion |
|
Samsung Electronics Co Ltd
KO:005930
|
Korea | ₩110.16 Trillion |
Liability Composition Analysis (1985–2025)
This chart breaks down Eli Lilly and Company's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Eli Lilly and Company balance sheet assets.
Liquidity & Leverage Metrics
Eli Lilly and Company Total Liabilities Ratios Explained
Eli Lilly and Company total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.35 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 3.20 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.76 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Eli Lilly and Company's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Eli Lilly and Company (1985–2025)
The table below shows the annual total liabilities of Eli Lilly and Company from 1985 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $85.94 Billion | +33.36% |
| 2024-12-31 | $64.44 Billion | +21.26% |
| 2023-12-31 | $53.14 Billion | +37.27% |
| 2022-12-31 | $38.71 Billion | -2.36% |
| 2021-12-31 | $39.65 Billion | -2.83% |
| 2020-12-31 | $40.81 Billion | +11.54% |
| 2019-12-31 | $36.59 Billion | +10.87% |
| 2018-12-31 | $33.00 Billion | -0.94% |
| 2017-12-31 | $33.31 Billion | +34.73% |
| 2016-12-31 | $24.73 Billion | +17.86% |
| 2015-12-31 | $20.98 Billion | +0.28% |
| 2014-12-31 | $20.92 Billion | +18.81% |
| 2013-12-31 | $17.61 Billion | -10.28% |
| 2012-12-31 | $19.62 Billion | -2.48% |
| 2011-12-31 | $20.12 Billion | +8.26% |
| 2010-12-31 | $18.59 Billion | +3.64% |
| 2009-12-31 | $17.94 Billion | -20.21% |
| 2008-12-31 | $22.48 Billion | +68.11% |
| 2007-12-31 | $13.37 Billion | +21.83% |
| 2006-12-31 | $10.97 Billion | -20.41% |
| 2005-12-31 | $13.79 Billion | -1.13% |
| 2004-12-31 | $13.95 Billion | +17.07% |
| 2003-12-31 | $11.91 Billion | +10.63% |
| 2002-12-31 | $10.77 Billion | +15.42% |
| 2001-12-31 | $9.33 Billion | +7.94% |
| 2000-12-31 | $8.64 Billion | +10.65% |
| 1999-12-31 | $7.81 Billion | -4.33% |
| 1998-12-31 | $8.17 Billion | +5.07% |
| 1997-12-31 | $7.77 Billion | -5.30% |
| 1996-12-31 | $8.21 Billion | -8.61% |
| 1995-12-31 | $8.98 Billion | -1.88% |
| 1994-12-31 | $9.15 Billion | +81.05% |
| 1993-12-31 | $5.05 Billion | +33.70% |
| 1992-12-31 | $3.78 Billion | +13.45% |
| 1991-12-31 | $3.33 Billion | -9.33% |
| 1990-12-31 | $3.68 Billion | +75.78% |
| 1989-12-31 | $2.09 Billion | +2.63% |
| 1988-12-31 | $2.04 Billion | -7.91% |
| 1987-12-31 | $2.21 Billion | +19.18% |
| 1986-12-31 | $1.86 Billion | +18.53% |
| 1985-12-31 | $1.57 Billion | -- |
About Eli Lilly and Company
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 7… Read more